Enovis (NYSE:ENOV) Posts Earnings Results, Beats Estimates By $0.11 EPS

Enovis (NYSE:ENOV) posted its quarterly earnings results on Thursday. The company reported $0.88 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.11, FiscalAI reports. The company had revenue of $558.73 million for the quarter, compared to the consensus estimate of $557.12 million. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The firm’s quarterly revenue was up 1.8% compared to the same quarter last year. During the same period last year, the company posted $0.75 EPS.

Here are the key takeaways from Enovis’ conference call:

• Enovis delivered 5% organic sales growth in Q3, led by 6% growth in Recon; P&R grew 3%. Adjusted EPS rose 17% to $0.88, while adjusted EBITDA margin expanded 120 basis points to 18.5%.
• The company raised its adjusted EBITDA outlook to $428 million–$438 million and adjusted EPS outlook to $3.58–$3.79, while maintaining expected organic growth of about 5%. It also reaffirmed its goal of greater than 25% free-cash-flow conversion in 2026.
• Management described markets as volatile, citing choppy U.S. hip and knee demand, challenging Western European conditions, and Middle East conflict that reduced total company growth by about 40 basis points. Inflation in raw materials, freight and distribution also pressured costs, partly offset by tariff refunds.
• Enovis expects to close its eCential Robotics acquisition by year-end and is investing in talent and technology ahead of integration. Management expects to bring a knee robot to market within two years, with shoulder to follow, and said customer feedback has been encouraging.
• The board authorized a $200 million share repurchase program, which management said it will use opportunistically while targeting leverage of 2.5–3.5 times. Net leverage was 2.9 times at quarter-end and is expected to rise about half a turn after the eCential deal closes.

Enovis Trading Down 5.1%

Shares of Enovis stock traded down $1.46 during trading on Friday, reaching $27.16. 2,304,734 shares of the stock were exchanged, compared to its average volume of 1,786,351. The company has a quick ratio of 1.00, a current ratio of 2.15 and a debt-to-equity ratio of 0.82. Enovis has a 1 year low of $16.70 and a 1 year high of $32.41. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of 8.04 and a beta of 1.31. The stock’s fifty day moving average is $19.91 and its 200 day moving average is $23.09.

Insider Buying and Selling

In other Enovis news, insider Oliver Engert acquired 5,140 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The shares were acquired at an average price of $19.46 per share, with a total value of $100,024.40. Following the completion of the purchase, the insider directly owned 61,238 shares of the company’s stock, valued at approximately $1,191,691.48. The trade was a 9.16% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Damien Mcdonald bought 13,035 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was bought at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the purchase, the chief executive officer owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. The trade was a 5.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders bought 23,293 shares of company stock valued at $449,599. 2.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

ENOV has been the topic of several research reports. BTIG Research boosted their price target on Enovis from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday. BMO Capital Markets set a $27.00 price objective on shares of Enovis in a research note on Tuesday, September 1st. Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Citigroup restated a “market outperform” rating on shares of Enovis in a research report on Wednesday, September 2nd. Finally, Needham & Company LLC lifted their price objective on shares of Enovis from $34.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $38.62.

Key Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q3 adjusted earnings were $0.88 per share, beating estimates of about $0.77 and topping $0.75 a year earlier. Revenue of $558.7 million slightly exceeded forecasts and grew 1.8% year over year. Enovis Q3 2026 results
• Positive Sentiment: Enovis raised its 2026 EPS guidance to $3.58–$3.79, signaling improved earnings expectations. Guidance and repurchase announcement
• Positive Sentiment: The company authorized a $200 million share-repurchase program, which could support per-share results and signal confidence in its prospects. Share-buyback announcement
• Positive Sentiment: Wells Fargo raised its target to $37 and maintained an Overweight rating; Needham lifted its target to $38 and BTIG to $42, both with Buy ratings. Wells Fargo analyst rating
• Neutral Sentiment: Canaccord lowered its price target from $45 to $42 but kept a Buy rating. Reports also highlighted product innovation and market-share gains, though market volatility remains a factor. Product innovation and share gains

About Enovis

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.